The simple reason that MSB has not done the trial that FDA has requested (many times) is that such a trial has already been done: by Osiris.
And guess what: the product failed to meet the endpoints (the data is all published: A Phase 3 Randomized Study of Remestemcel-L versus Placebo Addedto Second-Line Therapy in Patients with Steroid-Refractory AcuteGraft-versus-Host Disease).
That means it didn't work. It might well work in children but MSB was never going to repeat a study that would doom the product.
CEO Itescu needs to go, page-181
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.010(1.09%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 93.5¢ | 92.0¢ | $520.3K | 561.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 249658 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 73740 | 24 |
View Market Depth
| Last trade - 11.08am 11/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |